In clinical trials, semaglutide proved to be superior to placebo, with weight loss reaching 15%, suggesting its superiority over other non-GLP-1 RA anti ... and physical activity in a diary ...

researchers reported decreased odds among patients using GLP-1 RAs when evaluating mortality. Notably, this finding was not significant. “We observed that GLP-1 RA use shows a signal toward ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) continue to skyrocket in popularity as both approved and off-label treatments for weight loss. However, their widespread use raises ...

Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them. (HealthDay News) — Both glucagon-like peptide-1 receptor agonists ...

This study found that using GLP-1 RAs and SGLT2is for type 2 diabetes treatment offers potential neuroprotections against Alzheimer disease and related dementias. HealthDay News — Both glucagon ...

analogs and receptor agonists (GLP-1 RAs) are relatively new players in the medical landscape, but they’ve quickly gained attention for their effects on blood glucose, metabolism, weight loss ...

GLP-1 RAs and SGLT2 inhibitors significantly reduce cardiovascular events and heart failure risk in older adults with type 2 diabetes compared to DPP-4 inhibitors. The study utilized health ...

The Centers for Medicare and Medicaid Services recently announced—without explanation—that it would not proceed with a proposal initiated by the Biden Administration to cover weight-loss drugs ...

GLP-1 RAs can reduce liver fat ... The effects of weight-lowering pharmacotherapies on physical activity, function and fitness: a systematic review and meta-analysis of randomized controlled ...

Driven by the new drug approvals (for different applications), and extensive R&D efforts of the companies (to enhance delivery mechanisms of GLP-1 drugs), the market is anticipated to witness ...

Moving forward, a similar study among patients taking GLP-1 RAs for obesity also is warranted, said Shapiro. “ It’s a different subset of people.” ...